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Abstract
Background: Autograft has been widely used in various orthopedic and dental surgery for its superior
osteogenicity, osteoinductivity and osteoconductivity. But the available volume of the autograft is limited and the
efficacy of it is highly affected by the condition of the patients. Therefore, growth factors such as Escherichia coli
bone morphogenetic protein-2 (ErhBMP-2) has been widely used in some countries and regions with various
carriers that could affect the effects of the growth factors. Demineralized bone matrix (DBM) has been widely used
as a bone graft substitute and growth factor carrier, but its effect as a carrier of ErhBMP-2 was less investigated.
Materials and methods: Rat calvaria defect model was used in this study. We implanted ErhBMP-2 with DBM or
hydroxyapatite (HA) as a carrier in 8 mm calvaria defect and compared their bone regeneration effect in 4th week
and 8th week after implantation with micro-CT and histology. The data was analyzed with one-way ANOVA
method with Bonferroni post-hoc analysis.
Result: The group with DBM as the carrier showed significantly higher bone volume and bone thickness than the
groups with HA as the carrier in both weeks. And the histology sections showed less adipose tissue formed in the
groups with DBM as the carrier.
Conclusion: DBM could be a better carrier for ErhBMP-2 than HA.
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Background
Autologous bone graft has been widely used in trauma,
spine, and dental surgery to promote bone regeneration
[1]. But in the cases of large bone defects, multiple bone
harvesting history or metabolic bone diseases, the
autologous bone graft could be inadequate for use [2].
Therefore, bone substitutes with growth factors, such as
demineralized bone matrix (DBM) with Escherichia coli
recombinant human bone morphogenetic protein-2
(ErhBMP-2) have been widely used for promoting bone re-
generation [3–7]. The ErhBMP-2 has been proved to have
comparable osteoinductivity with the mammalian cell de-
rived BMP-2 at both pre-clinical and clinical level, which
also had advantage of easy accessing and lower cost [8, 9].
The carriers immobilize the growth factor at the particular
site for a sufficient period for inducing bone formation and
affects the therapeutic effect of BMP-2 [7]. Hydroxyapatite
(HA) is an osteoconductive calcium phosphate ceramic that
has a similar chemical structure with inorganic component
of bone and have been proved to be a carrier for ErhBMP-2
[8, 10–13]. However, it had low fracture toughness and de-
gradability, and the remnant HA impedes bone remodeling
that made it a less optimal carrier [1, 14]. Demineralized
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bone matrix (DBM) is another BMP-2 carrier, which is
both osteoinductive and degradable [15, 16]. It has been
practiced over several years for its safety and excellent bio-
compatibility as both scaffold for bone regeneration and
carrier for growth factors [17–19]. But as far as we know,
no direct comparison was conducted between the effect of
HA and DBM as the carrier of ErhBMP-2. Therefore, we
loaded ErhBMP-2 on HA and DBM and compared their ef-
fect on bone regeneration with rat calvaria defect model.
Method
Rat calvarial defect model
The procedures that involved the use of animals for the
rat calvarial defect experiment were approved by the
international animal care and use committee (SNUH
IACUC No.13–0348). For animal welfare and reduction
of animal number, a group of data from a previously
published article with the same setting as in this study
was used [20]. Eight-week-old male Sprague-Dawley rats
(200–220 g, total N = 130) were used for the animal ex-
periment, all animals were kept in a 12:12 dark/light
cycle, specific-pathogen-free cage and were provided
with abundant food and water. The experiments were
performed after 1 week of stabilization period. The HA
granules with 0.6 mm to 1mm size were soaked into the
0.15 ml saline containing different dosage of BMP for 5
min. In the groups with DBM as carrier, the BMP was
injected into the syringe containing DBM. After the car-
riers were soaked with BMP-2, the carriers were gently
deposited inside the defect. The animals were randomly
assigned to following 5 groups: HA (Novosis, CGBio,
Korea) 25 mg; DBM 0.05 ml; ErhBMP-2 25 μg (Novosis,
CGBio, Korea) + HA 25mg (Novosis, CGBio, Korea);
ErhBMP-2 2.5 μg (Novosis, CGBio, Korea) + HA 25mg
(Novosis, CGBio, Korea); ErhBMP-2 2.5 μg (Novosis,
CGBio, Korea) +DBM 0.05ml (Rafugen DBM gel, Cell-
mud, Korea). The animals were euthanized in their 4th and
8th weeks after surgery, and each group had 13 animals at
each time point.
Animals were anesthetized with intraperitoneal injec-
tions of 20 mg/kg Zoletil and 10mg/kg xylazine. After
an 8mm calvarial defect was made with a high speed
trephine burr. The BMP-2 containing carrier was
implanted in the defect and the defect was sutured layer
by layer [21].
All animals were sacrificed with a CO2 chamber under
deep anesthesia at their 4th or 8th week after experiments.
The calvaria were harvested and fixed in 10% formalin for
micro-CT evaluation and histological assessments.
Micro-CT
The samples were scanned with a Skyscan 1172 micro-
CT scanner (Bruker, Belgium) with the following format:
pixel size of 11.93 μm, Al filter of 0.5 mm, energy of 70
kV, current of 141 μA, rotation step of 0.4°. The raw im-
ages were reconstructed using the NRecon package
(Bruker, Belgium) and analyzed with the CT Analyzer
software (CT-An, Bruker, Belgium). The threshold
values in grayscale of the newly-formed bone were re-
ferred to the values of native bone and was set as 110 to
240. Bone morphometric parameters of newly formed
bone inside the defect, including percent bone volume
(BV/TV), bone surface/volume ratio (BS/BV), trabecular
bone pattern factor (Tb.Pf), structure model index
(SMI), trabecular bone thickness (Tb.Th), trabecular
number (Tb.N), trabecular separation (Tb.Sp), and de-
gree of anisotropy (DA) were analyzed. The data used in
the DBM/ErhBMP-2(2.5 μg) group was previously used
in another published article [9].
Histology
The samples were fixed in 10% formalin and sequentially
dehydrated in 80 to 100% ethyl alcohol, infiltrated, and
embedded in Technovit 7200 resin (EXAKT, Germany).
The resin was solidified with a polymerization system
(EXAKT, Germany), the hardened resin blocks were
sectioned by using a cutting system (EXAKT, Germany) to
200 μm thick slices, and the slices were ground to a
thickness of 50 μm by using a grinding system (EXAKT,
Germany). The ground slices were stained with
hematoxylin and eosin and the stained bone formations in
the scaffolds were observed with an optical microscope.
Statistic
In the micro-CT analysis, the two rhBMP-2 groups were
compared with one-way ANOVA method and followed
by Bonferroni post-hoc analysis with SPSS 20 (IBM
Corp, Armonk, NY: IBM Corp). P value less than 0.05
was deemed as statistically significant. The data were
presented as mean and standard deviation.
Result
Micro-CT
Effect of HA and DBM as bone substitute
In the 4th week, DBM group had significantly higher
BV/TV, Tb. Th, and Tb. N, and significantly lower BS/
BV, Tb,Pf and SMI than the HA group. The parameters
indicated the new bone in the DBM group had more
volume, number, thicker structure, more continuity,
more sphere void, and less complex surface than the
new bone in the HA group (Fig. 1a).
In the 8th week, the DBM group had similar BV/TV
with HA, but significantly higher Tb. Sp and Tb. Th,
and significantly lower Tb. Pf and SMI. The parameters
indicated the new bone in the DBM group still had more
continuity and sphere void, but the percent bone volume
became similar to that of HA group. Moreover, the sep-
aration between the newly formed bone in the DBM
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group became significantly wider than that in HA group
(Fig. 1b).
Effect of HA and DBM as carriers of BMP-2
In the 4th week, DBM/ErhBMP-2(2.5 μg) group had 52
and 30% higher BV/TV than HA/ErhBMP-2(2.5 μg)
group and HA/ErhBMP-2(25 μg) group, with statistical
significance (Fig. 2a) Also, DBM/ErhBMP-2(2.5 μg)
group had significantly higher Tb. Th than the HA/
ErhBMP-2(2.5 μg) group and HA/ErhBMP-2(25 μg)
group without significant difference in Tb. N or Tb.Sp.
The significantly lower SMI in DBM/ErhBMP-2(2.5 μg)
group indicated a more spherical structured bone
formed in the DBM/ErhBMP-2(2.5 μg) group.
In the 8th week, the BV/TV of DBM/ErhBMP-
2(2.5 μg) group was 52 and 65% higher than that of HA/
ErhBMP-2(2.5 μg) group and HA/ErhBMP-2(25 μg)
group, with statistical significance. Consistent with the
result in the 4th week, the DBM/ErhBMP-2(2.5 μg)
group had significantly higher Tb. Th than the HA/
ErhBMP-2(2.5 μg) group and HA/ErhBMP-2(25 μg)
group. The significantly lower SMI in DBM/ErhBMP-
2(2.5 μg) group indicated more spherical structured bone
formed in the DBM/ErhBMP-2(2.5 μg) (Fig. 2b).
The parameters indicated the bone formed DBM/
ErhBMP-2(2.5 μg) group maintained its advantage in
bone volume, and the bone had more sphere void and
more continuity structure. Additionally, the Tb. Th was
slightly but significantly higher in DBMErhBMP-
2(2.5 μg) group in the 4th week, while in the 8th week,
the Tb. Th of DBM/ErhBMP-2(2.5 μg) group became
28% higher than that of the other two groups. The
Fig. 1 micro-CT results of the HA and DBM groups. a Micro-CT results in the 4th week. DBM group had significantly higher BV/TV, Tb. Th, and Tb.
N, and significantly lower BS/BV, Tb,Pf and SMI than the HA group. b Micro-CT results in the 8th week. The DBM group had similar BV/TV with
HA, but significantly higher Tb. Sp and Tb. Th, and significantly lower Tb. Pf and SMI. *, p value is less than 0.05
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results consistently showed the DBM/ErhBMP-2(2.5 μg)
group achieved the best bone regeneration at both time
points (Fig. 3).
Histology
The histology sections showed consistent with micro-CT
result. In the 4th week, the DBM group showed more
bone than HA. The HA/ErhBMP-2(25 μg) group had
slightly more bone than HA/ErhBMP-2(2.5 μg) group.
The DBM/ErhBMP-2(2.5 μg) group had the most bone
formed. Additionally, the bone in DBM/ErhBMP-
2(2.5 μg) group showed denser construct and less fatty
tissue formed inside the newly generated bone than the
other groups (Fig. 3).
In the 8th week, HA and DBM showed similar bone
regeneration. HA/ErhBMp-2(25 μg) group showed similar
Fig. 2 micro-CT results of groups with BMP-2. a Micro-CT results in the 4th week. DBM/ErhBMP-2(2.5 μg) group had significantly higher BV/TV
and Tb. Th than HA/ErhBMP-2(2.5 μg) group and HA/ErhBMP-2(25 μg) group. Also, the DBM/ErhBMP-2(2.5 μg) group had significantly lower SMI
than the other two groups. b Micro-CT results in the 8th week. The DBM/ErhBMP-2(2.5 μg) group had significantly higher BV/TV and Tb. Th and
significantly lower SMI than the other two groups. *, p value is less than 0.05, compare with HA/ErhBMP-2(25 μg) group. $, p value is less than
0.05, compare with HA/ErhBMP-2(2.5 μg) group
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bone volume and more sphere-shaped void with HA/
ErhBMP-2(2.5 μg) group. The DBM/ErhBMP-2(2.5 μg)
group had the most bone generated in the defect, and the
bone was the thickest among the groups. Also, the DBM/
ErhBMP-2(2.5 μg) group had the least fatty tissue in the
newly formed bone (Fig. 4).
Discussion
Critical bone defect that cannot heal spontaneously re-
quires bone grafting to provide sufficient endogenous re-
generation. The standard grafting material is still the
autologous bone, despite its complications. Following
the development in the tissue engineering, the ErhBMP-
2 has been used in the clinic for promoting bone regen-
eration [8, 22]. Despite the inspired outcomes in pre-
clinical studies, the effectiveness of BMP-2 in clinical
cases still need to be furtherly proved, such as non-
union. One possible reason is the fast release from the
used carrier that mostly determines the effect of the
BMP-2, therefore, choosing an appropriate carrier for
the ErhBMP-2 remains to be an active area of research.
DBM is an attractive bone substitute that can release the
BMP-2 with a pattern of a 4-day burst release followed
with a 14-day continuous release [16, 23].
The effect of DBM as the carrier was compared
in vivo with HA, another widely used bone substitute
Fig. 3 micro-CT images. ErhBMP-2 2.5 μg + DBM had the best bone regeneration in 4th and 8th week. No significant difference was observed
between ErhBMP-2 2.5 μg + HA and ErhBMP-2 25 μg + HA at both time points. DBM group achieved faster bone regeneration than HA in the 4th
week, but had similar bone formed with HA group in the 8th week. The data in DBM + ErhBMP-2 group was reported in a previous article [20]
Fig. 4 Histology sections. a Histology sections in the 4th week. ErhBMP-2 2.5 μg + DBM showed significantly more solid bone regeneration, less
adipose tissue formation than ErhBMP-2 25 μg + HA and ErhBMP-2 2.5 μg + HA groups. In both groups with HA as carrier, cyst-like bone and
abundant adipose tissue formed in the defect. b Histology sections in the 8th week. ErhBMP-2 2.5 μg + DBM group still had the most bone
regeneration. ErhBMP-2 25 μg + HA had more adipose tissue formed inside the defect and more hollow structure compared with 4th week. The
bone in ErhBMP-2 2.5 μg + HA had less cyst-like bone and adipose tissue than ErhBMP-2 25 μg + HA group had. The DBM group had less bone
compared with its 4th week. The green triangles indicated the HAP granules and the cyan diamonds indicated the newly formed bone. The data
in DBM + ErhBMP-2 group was reported in a previous article [20]
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with a rapid BMP-2 releasing pattern [24]. In the com-
parison of mere DBM and HA, the micro-CT showed
similar bone regeneration on the 8th week. But with
BMP-2 added, the DBM showed significantly and
obviously more bone regeneration at both time points
compared with its same dosage counterpart. The
possible reasons might be the growth factors that already
contained in the DBM that ErhBMP-2 synergistically
elevated bone regeneration with ErhBMP-2 and its su-
perior transfer rate and releasing pattern of BMP-2 [19].
More surprisingly, we noticed even adding 10 times dos-
ages of BMP-2 in HA did not significantly increased
bone regeneration at both time points, which furtherly
proved merely increasing the dosage of ErhBMP-2 can-
not guarantee a better bone regeneration.
In previous studies, it has been attempted to optimize
the release of rhBMP-2 from carrier to achieve better
bone regeneration. Zhu et al. investigated a collagen-
binding rhBMP-2, and this structure modified rhBMP-2
achieved significantly slower release and better bone for-
mation than the commercial BMP-2 while both with
DBM as a carrier [17]. Also, a heparin conjugated carrier
system was proved to reduce adipose tissue formation
and enhance bone generation by ErhBMP-2 [25, 26].
However, the new product listed above remained in pre-
clinical experiment phases and needed further investiga-
tion of their safety and effect character. Compare with
the newly fabricated material and modified rhBMP-2,
the HA, DBM, and rhBMP-2 used in this study were all
commercially available. Therefore, the result from this
study might offer more practical evidence for using
ErhBMP-2 in a clinical situation and provide a possible
combination of ErhBMP-2 and its carrier system.
On the other side, though DBM/ErhBMP-2(2.5 μg)
performed the best bone regeneration, DBM itself might
not be an ideal carrier. Firstly, all DBM clinical product
is from a human donor. Though donor qualification
process is rigorous and stringent, using DBM still has a
risk of disease transmission [15]. Moreover, the effi-
ciency could also be affected by donor variability, like
age and gender [27]. Secondly, the product of DBM was
in powder shape and it requires other carriers for hand-
ling, and the carriers used to mix DBM could bring var-
iety in the final efficacy [27].
In selecting the bone defect model, we used a rat
calvaria defect model, which has been widely used for
generating standardized defects [28]. But it cannot simu-
late all bone defect diseases in a clinical situation. Be-
cause the calvaria was composed of flat bone and healed
through intramembranous ossification, and it cannot be
used to assess the material under physiological mechan-
ical loads [28, 29]. The micro-CT analysis might over-
estimate the bone formation in groups with HA due to
the difficulties in separating HA from newly formed
bone. But even considering the possible overestimated
bone volume in HA group, the groups with DBM as the
carrier showed higher bone volume. Therefore, with the
consistent trend observed from histology sections, we
believe the result from micro-CT could be considered
reliable. In current stage of study, the release kinetics,
transfer rate or the degradation characteristics of the
two carriers were not investigated, which brought diffi-
culties in furtherly interpreting the reasons of the super-
ior effect of the DBM to HA. In further studies, the
reasons of the better performance of DBM should be
elucidated. At current stage of study, the surface morph-
ology of the DBM or HA was not obtained, which
brought hassles in analyzing the possible reasons of the
result and was a limitation of this study. Additionally,
the histomorphometry analysis result should be per-
formed to bring more concise results. The performance
of DBM as a carrier of ErhBMP-2 should be evaluated
with defect models that can simulate spinal fusion and
long bone defect, in which bone regenerates through
endochondral ossification, blood flow might dilute the
dosage of ErhBMP-2 and mechanical stress could be
load [28, 29].
Conclusion
DBM presented a potent carrier of ErhBMP-2 the in-
duced significantly better bone regeneration than HA.
The combination of DBM and ErhBMP-2 that could be
a feasible bone substitute for augmentation of bone
defect.
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